期刊文献+

抗癫痫药物的遗传学研究进展 被引量:1

下载PDF
导出
摘要 抗癫痫药物治疗是癫痫的主要治疗方法,但在治疗过程中还存在很多问题,主要是对抗癫痫药物的反应性(有效性、毒性和耐药性)难以预测,而遗传因素在决定个体对抗癫痫药物治疗反应性中起着重要作用。遗传因素决定癫痫的类型,影响抗癫痫药物的代谢动力学和效应动力学,目前已经发现多种能够影响抗癫痫药物反应性的候选基因,并且认为多药耐药癫痫的发生与遗传因素密切相关。本文将对抗癫痫药物的遗传学研究的最新进展进行综述,并评价其在癫痫临床个体化治疗中的作用。
出处 《国际神经病学神经外科学杂志》 2010年第6期524-527,共4页 Journal of International Neurology and Neurosurgery
  • 相关文献

参考文献18

  • 1Nakken KO, Taub~ll E. Drug-resistant epilepsy. Tidsskr Nor Laegeforen, 2009, 129(19): 1986-1959.
  • 2杜强,丁美萍.左乙拉西坦在癫痫治疗中的作用[J].国际神经病学神经外科学杂志,2009,36(2):132-135. 被引量:9
  • 3Stafstrom CE. Mechanisms of action of antiepileptic drags: the search for synergy. Curr Opin Neurol, 2010 , 23 ( 2 ) : 157-163.
  • 4Tare SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin Pharmacother, 2007 , 8(10) : 1441-1449.
  • 5Lage H. MDR1/P-glycoprotein (ABCBI) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets, 2006, 7(7) : 813-821.
  • 6Bia~ecka M, Hnatyszyn G, Bielicka-Cymerman J, et al. The effect of MDR 1 gene polymorphism in the pathogenesis and the treatment of drug-resistant epilepsy. Neurol Neurochir Pol, 2005, 39(6) : 476-481.
  • 7Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain, 2006, 129 ( Pt 1 ) : 18-35.
  • 8Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab, 2008, 9(8) : 738-784.
  • 9King CD, Rios GR, Green MD, et al. UDP-glucuronosyl transferases. Curt Drug Metab, 2000, 1(2) : 143-161.
  • 10Meldrum BS, Rogawski MA. Molecular targets for antiepilep- tic drug development. Neurotherapeutics, 2007, 4 ( 1 ) : 18-61.

二级参考文献24

  • 1Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure, 2003, 12(8) : 617-620.
  • 2Specchio LM, Gambardella A, Giallonardo AT, et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res, 2006, 71(1) : 32-39.
  • 3Berkovic SF, Knowlton RC, Leroy RF, et al. Levetiracetam NO 1057 Study Group. Placebo-controlled study of levetirace- tam in idiopathic generalized epilepsy. Neurology, 2007, 69 (18): 1734-1736.
  • 4Specchio N, Boero G, Michelucci R, et al. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia, 2008, 49(4) : 663-669.
  • 5Verrotti A, Cerminara C, Coppola G, et al. Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol, 2008, 50( 1 ): 29-32.
  • 6Arroyo S, Crawford P. Safety profile of levetiracetam. Epileptic Dis, 2003, 5(1): 57-63.
  • 7Gomer B, Wagner K, Frings L, et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav, 2007, 10 ( 3 ) : 486-494.
  • 8Cramer JA, Van Hammre G; N132 Study Group, Maintenance of improvement in health-related quality of life during long-term treatment with levetiraeetam. Epilepsy Behav, 2003, 4(2) : 118-123.
  • 9Von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics, 2007 Jan ; 4 ( 1 ) :84-87.
  • 10Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714 ) , a high-affinity ligand for the synaptic vesicle protein, SV2 A. Br J Pharmacol, 2008, 154(8) : 1662-1671.

共引文献8

同被引文献4

引证文献1

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部